The global cancer monoclonal antibodies market size is estimated to reach around USD 410.95 billion by 2032, increasing from USD 89.06 billion in 2023.
Cancer Monoclonal Antibodies Market Size Estimated to Reach USD 410.95 Billion by 2032 Read More »
Terran Biosciences, Inc. has received notice of allowance from the United States Patent and Trademark Office (USPTO) for four US patents covering a number of breakthroughs in the psychedelic therapeutic space.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
IDEAYA Biosciences, Inc. today announced that, on November 30, 2023 , the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company’s common stock to a newly hired employee.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023.
The clearance positions BD and partner Babson Diagnostics to support blood collection from community sites such as pharmacies.
BD receives 510(k) clearance for fingerstick blood test sample collection device Read More »
TD Cowen analysts said it is “unclear if and when FDA will finalize the rule as it has faced considerable opposition.”
White House sets April target for finalization of FDA rule on lab developed tests Read More »
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
MEDSIR, a global leader in oncology research, today presented significant breakthroughs in the fight against aggressive breast cancer at the 46th San Antonio Breast Cancer Symposium (SABCS) that have the potential to transform the lives of breast cancer patients.
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023 Read More »
